GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » Price-to-Tangible-Book

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Price-to-Tangible-Book : 0.59 (As of Apr. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-26), Oramed Pharmaceuticals's share price is $2.39. Oramed Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $4.06. Hence, Oramed Pharmaceuticals's Price to Tangible Book Ratio of today is 0.59.

The historical rank and industry rank for Oramed Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

ORMP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.54   Med: 3.06   Max: 6.15
Current: 0.59

During the past 13 years, Oramed Pharmaceuticals's highest Price to Tangible Book Ratio was 6.15. The lowest was 0.54. And the median was 3.06.

ORMP's Price-to-Tangible-Book is ranked better than
92.38% of 1220 companies
in the Biotechnology industry
Industry Median: 2.68 vs ORMP: 0.59

A closely related ratio is called PB Ratio. As of today, Oramed Pharmaceuticals's share price is $2.39. Oramed Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $4.06. Hence, Oramed Pharmaceuticals's P/B Ratio of today is 0.59.


Oramed Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Oramed Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Price-to-Tangible-Book Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.97 2.51 6.00 3.14 0.57

Oramed Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 0.58 0.95 0.71 0.57

Competitive Comparison of Oramed Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Oramed Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Price-to-Tangible-Book falls into.



Oramed Pharmaceuticals Price-to-Tangible-Book Calculation

Oramed Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=2.39/4.061
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Oramed Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.
Executives
Benjamin Shapiro director 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron director, 10 percent owner 142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov director 9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron director 2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz officer: Chief Commercial Officer 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer director MORAN 16, KFAR SABA L3 4428890
Netanel Derovan officer: Chief Legal Officer 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman officer: Chief Financial Officer 20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin director 36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz officer: Chief Commercial Officer MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank director 3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming director 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay officer: CFO, Treasurer and Secretary 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton officer: VP Business Development 13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman director HADASSA 6, TEL AVIV L3 6451306